Cancer Biomarkers Market Analysis and Forecast to 2034

Published Jul 22, 2025

Length 356 Pages

SKU # GIS20212747

Description

Cancer Biomarkers Market is anticipated to expand from $24.4 billion in 2024 to $60.3 billion by 2034, growing at a CAGR of approximately 8.4%. The Cancer Biomarkers Market is a critical segment within the healthcare industry, focusing on identifying biological molecules or conditions indicative of cancerous processes. These biomarkers are used in various clinical applications, from diagnosis and prognosis to treatment decision-making and monitoring. The market's significance lies in its potential to enable early detection and more precise targeting of therapies, thereby improving patient outcomes and reducing healthcare costs. This market is propelled by several key drivers, including advancements in medical technologies, an aging global population, and rising incidences of cancer worldwide. The integration of biomarkers in oncology research and clinical practice enhances the precision of therapeutic strategies, enabling personalized medicine approaches that tailor treatment to individual patient profiles. In the realm of diagnostics, cancer biomarkers are invaluable for their ability to detect cancer at an early stage, often before symptoms appear, which is crucial for successful treatment. Prognostic biomarkers offer insights into the likely course of cancer, helping healthcare providers anticipate the disease's progression and optimize treatment plans accordingly. Moreover, the Cancer Biomarkers Market is instrumental in the development and efficacy assessment of new cancer treatments. By identifying whether a particular therapeutic is effective for a patient, these biomarkers significantly streamline clinical trials and expedite the introduction of effective therapies to the market. Consequently, they are pivotal in the ongoing transformation of oncological care, moving it towards more targeted, efficient, and cost-effective modalities.

Key Market Drivers

Drivers in the Cancer Biomarkers Market include: Technological Advancements: Innovation in biotechnology and genetic sequencing has enhanced the detection and usability of cancer biomarkers, leading to more precise diagnostics and personalized medicine approaches. Rising Prevalence of Cancer: The increasing incidence of various cancers globally drives demand for early detection and monitoring, thus boosting the cancer biomarkers market. Government and Private Funding for Cancer Research: Significant investments by governments and private entities in cancer research encourage the development and validation of new biomarkers. Pharmaceutical and Biotech Collaboration: Collaborations between pharmaceutical companies and biotechnology firms are intensifying, aimed at identifying and commercializing novel biomarkers for therapeutic use. Awareness and Regulatory Support: Growing public health awareness and supportive regulatory policies regarding cancer prevention and early detection are facilitating wider adoption and development of biomarkers.

Key Restraints and Challenges

Key Market Restraints for the Cancer Biomarkers Market: Regulatory and Reimbursement Challenges: Complex approval processes and uncertain reimbursement policies can delay the adoption of new biomarkers. High Cost of Biomarker Development and Validation: The significant financial investment required for research, development, and clinical trials can be a barrier to entry for smaller companies. Technical Challenges in Biomarker Discovery and Validation: Identifying and validating effective biomarkers with high specificity and sensitivity remains technically challenging, impacting the pace of market growth. Data Privacy and Ethical Concerns: Handling and protection of genetic data raise ethical and privacy issues, potentially limiting the use of genetic biomarkers in cancer detection. Competition from Alternative Technologies: The rapid development of alternative diagnostic technologies, such as liquid biopsies and imaging techniques, may overshadow the growth of traditional biomarker products.

Key Players

Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, Agilent Technologies, AstraZeneca, Biocept, Biodesix, Bio-Rad Laboratories, Bristol-Myers Squibb, Caris Life Sciences Exact Sciences, Foundation Medicine, GE Healthcare, Guardant Health, Hologic, Illumina, Johnson & Johnson, Merck, Myriad Genetics, Nant Health Neo Genomics Laboratories, Novartis, Perkin Elmer, Pfizer, QIAGEN, Quanterix, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific,

Research Scope:

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

What to expect in the report:

Assess and project the market size for the Adaptive Reuse Architecture sector, segmented by type, application, and geography

Provide detailed insights and essential takeaways on qualitative and quantitative trends, market dynamics, structural framework, competitive landscape, and company profiling
Identify key factors driving market growth, alongside challenges, opportunities, drivers, and restraints
Determine elements that may constrain company involvement in international markets, aiding in the calibration of market share expectations and growth rates
Track and evaluate strategic developments such as acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
Conduct a strategic analysis of smaller market segments, emphasizing their potential, unique growth patterns, and impact on the broader market
Elucidate the competitive landscape, including an evaluation of business and corporate strategies, to monitor and analyze competitive progressions
Identify leading market participants based on business objectives, geographic presence, product offerings, and strategic initiatives

Chapter : 1: Sections : 1.1 Market Definition; 1.2 Market Segmentation; 1.3 Regional Coverage; 1.4 Key Company Profiles; 1.5 Key Manufacturers Profiles; 1.6 Data Snapshot : Executive Summary
Chapter : 2: Sections : 2.1 Summary; 2.2 Key Opinion Leaders; 2.3 Key Highlights of the Market, by Type; 2.4 Key Highlights of the Market, by Product; 2.5 Key Highlights of the Market, by Services; 2.6 Key Highlights of the Market, by Technology; 2.7 Key Highlights of the Market, by Application; 2.8 Key Highlights of the Market, by End user; 2.9 Key Highlights of the Market, by Installation type; 2.10 Key Highlights of the Market, by Functionality; 2.11 Key Highlights of the Market, by Stage; 2.12 Key Highlights of the Market, by North America; 2.13 Key Highlights of the Market, by Europe; 2.14 Key Highlights of the Market, by Asia-Pacific; 2.15 Key Highlights of the Market, by Latin America; 2.16 Key Highlights of the Market, by Middle East; 2.17 Key Highlights of the Market, by Africa : Premium Insights on the Market
Chapter : 3: Sections : 3.1 Market Attractiveness Analysis, by Region; 3.2 Market Attractiveness Analysis, by Type; 3.3 Market Attractiveness Analysis, by Product; 3.4 Market Attractiveness Analysis, by Services; 3.5 Market Attractiveness Analysis, by Technology; 3.6 Market Attractiveness Analysis, by Application; 3.7 Market Attractiveness Analysis, by End user; 3.8 Market Attractiveness Analysis, by Installation type; 3.9 Market Attractiveness Analysis, by Functionality; 3.10 Market Attractiveness Analysis, by Stage; 3.11 Market Attractiveness Analysis, by North America; 3.12 Market Attractiveness Analysis, by Europe; 3.13 Market Attractiveness Analysis, by Asia-Pacific; 3.14 Market Attractiveness Analysis, by Latin America; 3.15 Market Attractiveness Analysis, by Middle East; 3.16 Market Attractiveness Analysis, by Africa : Market Analysis
Chapter : 4: Sections : 4.1 Market Drivers; 4.2 Market Trends; 4.3 Market Restraints; 4.4 Market Opportunities; 4.5 Porters Five Forces Analysis; 4.6 PESTLE Analysis; 4.7 Value Chain Analysis; 4.8 4Ps Model; 4.9 ANSOFF Matrix : Market Strategy
Chapter : 5: Sections : 5.1 Parent Market Analysis; 5.2 Supply-Demand Analysis; 5.3 Consumer Buying Interest; 5.4 Case Study Analysis; 5.5 Pricing Analysis; 5.6 Regulatory Landscape; 5.7 Supply Chain Analysis; 5.8 Competition Product Analysis; 5.9 Recent Developments : Market Size
Chapter : 6: Sections : 6.1 Cancer Biomarkers Market Market Size, by Value; 6.2 Cancer Biomarkers Market Market Size, by Volume : Cancer Biomarkers Market Market, by Type
Chapter : 7: Sections : 7.1 Key Market Overview, Trends & Opportunity Analysis; 7.2 Market Size and Forecast, by Type; 7.2.1 Market Size and Forecast, by Genomic Biomarkers; 7.2.1 Market Size and Forecast, by Proteomic Biomarkers; 7.2.1 Market Size and Forecast, by Metabolomic Biomarkers; 7.2.1 Market Size and Forecast, by Epigenetic Biomarkers; 7.3 Market Size and Forecast, by Product; 7.3.1 Market Size and Forecast, by Assay Kits; 7.3.1 Market Size and Forecast, by Reagents; 7.3.1 Market Size and Forecast, by Instruments; 7.3.1 Market Size and Forecast, by Software; 7.4 Market Size and Forecast, by Services; 7.4.1 Market Size and Forecast, by Sample Preparation; 7.4.1 Market Size and Forecast, by Biomarker Validation; 7.4.1 Market Size and Forecast, by Biomarker Testing; 7.4.1 Market Size and Forecast, by Data Analysis; 7.5 Market Size and Forecast, by Technology; 7.5.1 Market Size and Forecast, by Next-Generation Sequencing; 7.5.1 Market Size and Forecast, by Polymerase Chain Reaction; 7.5.1 Market Size and Forecast, by Immunoassays; 7.5.1 Market Size and Forecast, by Mass Spectrometry; 7.5.1 Market Size and Forecast, by Chromatography; 7.6 Market Size and Forecast, by Application; 7.6.1 Market Size and Forecast, by Diagnostics; 7.6.1 Market Size and Forecast, by Drug Discovery and Development; 7.6.1 Market Size and Forecast, by Prognostics; 7.6.1 Market Size and Forecast, by Risk Assessment; 7.7 Market Size and Forecast, by End user; 7.7.1 Market Size and Forecast, by Hospitals; 7.7.1 Market Size and Forecast, by Research Laboratories; 7.7.1 Market Size and Forecast, by Pharmaceutical Companies; 7.7.1 Market Size and Forecast, by Biotechnology Companies; 7.7.1 Market Size and Forecast, by Academic Institutes; 7.8 Market Size and Forecast, by Installation type; 7.8.1 Market Size and Forecast, by On-Premise; 7.8.1 Market Size and Forecast, by Cloud-Based; 7.9 Market Size and Forecast, by Functionality; 7.9.1 Market Size and Forecast, by Detection; 7.9.1 Market Size and Forecast, by Monitoring; 7.9.1 Market Size and Forecast, by Profiling; 7.10 Market Size and Forecast, by Stage; 7.10.1 Market Size and Forecast, by Early Detection; 7.10.1 Market Size and Forecast, by Prognosis; 7.10.1 Market Size and Forecast, by Therapeutic Response; 7.10.1 Market Size and Forecast, by Recurrence : Cancer Biomarkers Market Market, by Region
Chapter : 8: Sections : 8.1 Overview; 8.2 North America; 8.3.1 Key Market Trends and Opportunities; 8.3.2 North America Market Size and Forecast, by Type; 8.3.3 North America Market Size and Forecast, by Genomic Biomarkers; 8.3.4 North America Market Size and Forecast, by Proteomic Biomarkers; 8.3.5 North America Market Size and Forecast, by Metabolomic Biomarkers; 8.3.6 North America Market Size and Forecast, by Epigenetic Biomarkers; 8.3.7 North America Market Size and Forecast, by Product; 8.3.8 North America Market Size and Forecast, by Assay Kits; 8.3.9 North America Market Size and Forecast, by Reagents; 8.3.10 North America Market Size and Forecast, by Instruments; 8.3.11 North America Market Size and Forecast, by Software; 8.3.12 North America Market Size and Forecast, by Services; 8.3.13 North America Market Size and Forecast, by Sample Preparation; 8.3.14 North America Market Size and Forecast, by Biomarker Validation; 8.3.15 North America Market Size and Forecast, by Biomarker Testing; 8.3.16 North America Market Size and Forecast, by Data Analysis; 8.3.17 North America Market Size and Forecast, by Technology; 8.3.18 North America Market Size and Forecast, by Next-Generation Sequencing; 8.3.19 North America Market Size and Forecast, by Polymerase Chain Reaction; 8.3.20 North America Market Size and Forecast, by Immunoassays; 8.3.21 North America Market Size and Forecast, by Mass Spectrometry; 8.3.22 North America Market Size and Forecast, by Chromatography; 8.3.23 North America Market Size and Forecast, by Application; 8.3.24 North America Market Size and Forecast, by Diagnostics; 8.3.25 North America Market Size and Forecast, by Drug Discovery and Development; 8.3.26 North America Market Size and Forecast, by Prognostics; 8.3.27 North America Market Size and Forecast, by Risk Assessment; 8.3.28 North America Market Size and Forecast, by End user; 8.3.29 North America Market Size and Forecast, by Hospitals; 8.3.30 North America Market Size and Forecast, by Research Laboratories; 8.3.31 North America Market Size and Forecast, by Pharmaceutical Companies; 8.3.32 North America Market Size and Forecast, by Biotechnology Companies; 8.3.33 North America Market Size and Forecast, by Academic Institutes; 8.3.34 North America Market Size and Forecast, by Installation type; 8.3.35 North America Market Size and Forecast, by On-Premise; 8.3.36 North America Market Size and Forecast, by Cloud-Based; 8.3.37 North America Market Size and Forecast, by Functionality; 8.3.38 North America Market Size and Forecast, by Detection; 8.3.39 North America Market Size and Forecast, by Monitoring; 8.3.40 North America Market Size and Forecast, by Profiling; 8.3.41 North America Market Size and Forecast, by Stage; 8.3.42 North America Market Size and Forecast, by Early Detection; 8.3.43 North America Market Size and Forecast, by Prognosis; 8.3.44 North America Market Size and Forecast, by Therapeutic Response; 8.3.45 North America Market Size and Forecast, by Recurrence; 8.3.46 United States; 8.3.47 United States Market Size and Forecast, by Type; 8.3.48 United States Market Size and Forecast, by Genomic Biomarkers; 8.3.49 United States Market Size and Forecast, by Proteomic Biomarkers; 8.3.50 United States Market Size and Forecast, by Metabolomic Biomarkers; 8.3.51 United States Market Size and Forecast, by Epigenetic Biomarkers; 8.3.52 United States Market Size and Forecast, by Product; 8.3.53 United States Market Size and Forecast, by Assay Kits; 8.3.54 United States Market Size and Forecast, by Reagents; 8.3.55 United States Market Size and Forecast, by Instruments; 8.3.56 United States Market Size and Forecast, by Software; 8.3.57 United States Market Size and Forecast, by Services; 8.3.58 United States Market Size and Forecast, by Sample Preparation; 8.3.59 United States Market Size and Forecast, by Biomarker Validation; 8.3.60 United States Market Size and Forecast, by Biomarker Testing; 8.3.61 United States Market Size and Forecast, by Data Analysis; 8.3.62 United States Market Size and Forecast, by Technology; 8.3.63 United States Market Size and Forecast, by Next-Generation Sequencing; 8.3.64 United States Market Size and Forecast, by Polymerase Chain Reaction; 8.3.65 United States Market Size and Forecast, by Immunoassays; 8.3.66 United States Market Size and Forecast, by Mass Spectrometry; 8.3.67 United States Market Size and Forecast, by Chromatography; 8.3.68 United States Market Size and Forecast, by Application; 8.3.69 United States Market Size and Forecast, by Diagnostics; 8.3.70 United States Market Size and Forecast, by Drug Discovery and Development; 8.3.71 United States Market Size and Forecast, by Prognostics; 8.3.72 United States Market Size and Forecast, by Risk Assessment; 8.3.73 United States Market Size and Forecast, by End user; 8.3.74 United States Market Size and Forecast, by Hospitals; 8.3.75 United States Market Size and Forecast, by Research Laboratories; 8.3.76 United States Market Size and Forecast, by Pharmaceutical Companies; 8.3.77 United States Market Size and Forecast, by Biotechnology Companies; 8.3.78 United States Market Size and Forecast, by Academic Institutes; 8.3.79 United States Market Size and Forecast, by Installation type; 8.3.80 United States Market Size and Forecast, by On-Premise; 8.3.81 United States Market Size and Forecast, by Cloud-Based; 8.3.82 United States Market Size and Forecast, by Functionality; 8.3.83 United States Market Size and Forecast, by Detection; 8.3.84 United States Market Size and Forecast, by Monitoring; 8.3.85 United States Market Size and Forecast, by Profiling; 8.3.86 United States Market Size and Forecast, by Stage; 8.3.87 United States Market Size and Forecast, by Early Detection; 8.3.88 United States Market Size and Forecast, by Prognosis; 8.3.89 United States Market Size and Forecast, by Therapeutic Response; 8.3.90 United States Market Size and Forecast, by Recurrence; 8.3.91 Local Competition Analysis; 8.3.92 Local Market Analysis : Competitive Landscape
Chapter : 9: Sections : 9.1 Overview; 9.2 Market Share Analysis; 9.3 Key Player Positioning; 9.4 Competitive Leadership Mapping; 9.5 Star Players; 9.6 Innovators; 9.7 Emerging Players; 9.8 Vendor Benchmarking; 9.9 Developmental Strategy Benchmarking; 9.10 New Product Developments; 9.11 Product Launches; 9.12 Business Expansions; 9.13 Partnerships, Joint Ventures, and Collaborations; 9.14 Mergers and Acquisitions : Company Profiles - Overview, Segments, Performance, Products, Key Strategies, SWOT Analysis
Chapter : 10: Sections : 10.1 Abbott Laboratories; 10.2 Adaptive Biotechnologies; 10.3 Agilent Technologies; 10.4 Agilent Technologies; 10.5 AstraZeneca; 10.6 Biocept; 10.7 Biodesix; 10.8 Bio-Rad Laboratories; 10.9 Bristol-Myers Squibb; 10.10 Caris Life Sciences Exact Sciences; 10.11 Foundation Medicine; 10.12 GE Healthcare; 10.13 Guardant Health; 10.14 Hologic; 10.15 Illumina; 10.16 Johnson & Johnson; 10.17 Merck; 10.18 Myriad Genetics; 10.19 Nant Health Neo Genomics Laboratories; 10.20 Novartis; 10.21 Perkin Elmer; 10.22 Pfizer; 10.23 QIAGEN; 10.24 Quanterix; 10.25 Roche Diagnostics; 10.26 Siemens Healthineers; 10.27 Sysmex Corporation; 10.28 Thermo Fisher Scientific

Pricing

Currency Rates

Single User Email from Publisher $4,750
Global Site License Email from Publisher $6,750

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now